Literature DB >> 23088382

Orbital cavernous haemangiomas: immunohistochemical study of proliferative capacity, vascular differentiation and hormonal receptor status.

Aanchal Gupta1, Venkatesh C Prabhakaran, Tom Dodd, Garry Davis, Dinesh Selva.   

Abstract

BACKGROUND/AIMS: Immunohistochemical characterisation of orbital cavernous haemangiomas (CHs) with respect to proliferative capacity, hormone receptor status and vascular differentiation.
METHODS: Eleven cases of orbital CHs were reviewed. Immunohistochemical stains for Mib-1, proliferating cell nuclear antigen (PCNA), Bcl-2, estrogen and progesterone receptors (ER & PR), CD31, D2-40, and VEGF were investigated in 11 specimens.
RESULTS: Immunohistochemical staining revealed positivity for PCNA in ten of the 11 cases (91%). Bcl-2 was positive in 8 cases (73%). VEGF and PR were each weakly positive in 3 cases. All cases were negative for Mib-1, ER and D2-40. The staining was localized around the endothelium.
CONCLUSION: This is the first study to characterise in detail the immunohistochemical features of orbital CHs. The proliferative markers PCNA and Mib-1 show discordant expression in these lesions and the expression of PCNA and Bcl-2 in the absence of Mib-1 is indicative of low proliferative potential. Small subsets of these tumors express PR and VEGF, which may partly explain the proliferative capacity of some orbital CHs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23088382     DOI: 10.3109/01676830.2012.711887

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  2 in total

1.  Clinico-epidemiological analysis of 1000 cases of orbital tumors.

Authors:  Hiroshi Goto; Naoyuki Yamakawa; Hiroyuki Komatsu; Masaki Asakage; Kinya Tsubota; Shun-Ichiro Ueda; Rei Nemoto; Kazuhiko Umazume; Yoshihiko Usui; Hideki Mori
Journal:  Jpn J Ophthalmol       Date:  2021-07-27       Impact factor: 2.447

2.  Vascular Endothelial Growth Factor Receptor Expression in Orbital Cavernous Malformations and Lymphatic Malformations.

Authors:  Ann Q Tran; Marissa K Shoji; Alexandra Levitt; Wendy W Lee
Journal:  Ophthalmol Vis Care       Date:  2021-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.